People taking tirzepatide injections lost more weight and were more likely to reach specific weight loss targets than those taking semaglutide, according to a new study.
Researchers from Truveta, a health data analytics company, analyzed electronic health records for more than 18,000 adults, all of whom had overweight or obesity, who were taking these medications in the real world between May 2022 and September 2023. The findings were published Monday in the JAMA Internal Medicine medical journal.
The FDA approved higher doses of both tirzepatide and semaglutide to treat weight loss, but the new study only looked at the doses to treat type 2 diabetes. About half of the people who were included in this study had type 2 diabetes, while the other half had no indication of a diabetes diagnosis in their health records and were likely taking these medications off-label for weight management at their doctor’s discretion.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Ozempic, Mounjaro users turning to protein shakes to help beef up musclesOzempic and Mounjaro users are increasingly turning to protein drinks as a convenient way to supplement protein consumption and combat excess muscle loss.
Read more »
Ozempic drugmaker is ‘ripping off the American people' with high prices, says Bernie SandersSen. Bernie Sanders, I-Vt., says the first question he is going to ask Novo Nordisk's CEO at a Senate committee hearing in September is why the drugmaker…
Read more »
Mounjaro Drug Tirzepatide Could Treat Sleep Apnea, Study FindsRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Read more »
Mounjaro Drug Tirzepatide Could Treat Sleep Apnea, Study FindsRobert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.
Read more »
I lost 42 pounds on Ozempic — this is the one risk I didn’t see comingExperts reveal why Ozempic appears to change people’s personalities
Read more »
GLP-1 Medicine Mounjaro May Be First Drug to Ease Sleep ApneaA medication used to manage type 2 diabetes has been found effective in treating sleep apnea.
Read more »